Drug-maker Ranbaxy Laboratories today said it has received approval from the US drug regulator to market and manufacture Ramipril, used in the treatment of cardiovascular diseases.
In a filing to the Bombay Stock Exchange, the pharmaceuticals firm said it has received final nod from US Food and Drug Administration (US FDA) for Ramipril capsules.
Ramipril, which can also be used for treating hypertension, is a bioequivalent to King Pharmaceuticals' Altace drug.
The drug will be available in the strength of 5mg and 10mg capsules.
The application for the drug was submitted by the company from its US-based subsidiary Ohm Laboratories' facility at New Jersey.
"Ranbaxy is pleased to receive this final approval for Ramipril capsules. This is the third Abbreviated New Dug Application (ANDA) approval that materialised specific to Ohm Laboratories, in the last two months," Ranbaxy Pharmaceuticals Inc Vice-President (Sales and Distribution) Jim Meehan said.
Shares of Ranbaxy were trading at Rs 139.70, down 1.13 per cent on the BSE.
Content Guide
